73 related articles for article (PubMed ID: 18277134)
1. Elucidating the molecular mechanisms of fibrinolytic shutdown after severe injury: The role of thrombin-activatable fibrinolysis inhibitor.
Coleman JR; Moore EE; Kelher MR; Jones K; Cohen MJ; Banerjee A; Silliman CC
J Trauma Acute Care Surg; 2023 Jun; 94(6):857-862. PubMed ID: 36787438
[TBL] [Abstract][Full Text] [Related]
2. Role of factor XIII in ischemic stroke: a key molecule promoting thrombus stabilization and resistance to lysis.
Marta-Enguita J; Navarro-Oviedo M; Machado FJDM; Bermejo R; Aymerich N; Herrera M; Zandio B; Pagola J; Juega J; Marta-Moreno J; Rodriguez JA; Páramo JA; Roncal C; Muñoz R; Orbe J
J Thromb Haemost; 2024 Apr; 22(4):1080-1093. PubMed ID: 38160727
[TBL] [Abstract][Full Text] [Related]
3. The acute coagulopathy of trauma is due to impaired initial thrombin generation but not clot formation or clot strength.
Harr JN; Moore EE; Wohlauer MV; Droz N; Fragoso M; Banerjee A; Silliman CC
J Surg Res; 2011 Oct; 170(2):319-24. PubMed ID: 21550061
[TBL] [Abstract][Full Text] [Related]
4. The In Vitro Effects of Pentamidine Isethionate on Coagulation and Fibrinolysis.
Al-Horani RA; Clemons D; Mottamal M
Molecules; 2019 Jun; 24(11):. PubMed ID: 31174390
[TBL] [Abstract][Full Text] [Related]
5. Targeting Tissue Factor Pathway Inhibitor with concizumab to improve haemostasis in patients with Glanzmann thrombasthenia: an in vitro study.
Dubut J; Goin V; Derray C; Huguenin Y; Fiore M
J Thromb Haemost; 2024 Jun; ():. PubMed ID: 38880178
[TBL] [Abstract][Full Text] [Related]
6. Clot formation and fibrinolysis assays reveal functional differences among hemostatic agents in hemophilia A plasma.
Holle LA; Pantazis JC; Turecek PL; Wolberg AS
Res Pract Thromb Haemost; 2024 Jan; 8(1):102337. PubMed ID: 38426025
[TBL] [Abstract][Full Text] [Related]
7. Concizumab improves clot formation in hemophilia A under flow.
Jewell MP; Ashour Z; Baird CH; Manco Johnson M; Warren BB; Wufsus AR; Pallini C; Dockal M; Kjalke M; Neeves KB
J Thromb Haemost; 2024 May; ():. PubMed ID: 38815755
[TBL] [Abstract][Full Text] [Related]
8. Levels of procoagulant factors and peak thrombin generation in relation to dementia risk in older adults: The Cardiovascular Health Study.
Harrington LB; Ehlert AN; Thacker EL; Jenny NS; Lopez O; Cushman M; Olson NC; Fitzpatrick A; Mukamal KJ; Jensen MK
Thromb Res; 2024 Mar; 235():148-154. PubMed ID: 38340522
[TBL] [Abstract][Full Text] [Related]
9. Mathematical models of coagulation-are we there yet?
Owen MJ; Wright JR; Tuddenham EGD; King JR; Goodall AH; Dunster JL
J Thromb Haemost; 2024 Jun; 22(6):1689-1703. PubMed ID: 38521192
[TBL] [Abstract][Full Text] [Related]
10. Fibrinolysis biomarker, thrombin, and activated protein C level alterations after coagulation activation depend on type of thrombophilia and clinical phenotype.
Reda S; Schwarz N; Müller J; McRae HL; Oldenburg J; Pötzsch B; Rühl H
Res Pract Thromb Haemost; 2024 Feb; 8(2):102351. PubMed ID: 38487678
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of fibrinolysis by recombinant factor VIIa in plasma from patients with severe hemophilia A.
Lisman T; Mosnier LO; Lambert T; Mauser-Bunschoten EP; Meijers JC; Nieuwenhuis HK; de Groot PG
Blood; 2002 Jan; 99(1):175-9. PubMed ID: 11756168
[TBL] [Abstract][Full Text] [Related]
12. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
[TBL] [Abstract][Full Text] [Related]
13. Overall haemostatic potential can be used for estimation of thrombin-activatable fibrinolysis inhibitor-dependent fibrinolysis in vivo and for possible follow-up of recombinant factor VIIa treatment in patients with inhibitors to factor VIII.
Antovic JP; Antovic A; He S; Tengborn L; Blombäck M
Haemophilia; 2002 Nov; 8(6):781-6. PubMed ID: 12410647
[TBL] [Abstract][Full Text] [Related]
14. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
15. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis.
Bouma BN; Mosnier LO
Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):375-81. PubMed ID: 15692247
[TBL] [Abstract][Full Text] [Related]
16. Effects of recombinant activated factor VII on thrombin-mediated feedback activation of coagulation.
Taketomi T; Szlam F; Bader SO; Sheppard CA; Levy JH; Tanaka KA
Blood Coagul Fibrinolysis; 2008 Mar; 19(2):135-41. PubMed ID: 18277134
[TBL] [Abstract][Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
